Recent Advances in Drug Delivery Approaches for Rheumatoid Arthritis

Abhishek      Verma; Preeti      Patel; Waleed   Hassan   Almalki; Amirhossein      Sahebkar; Balak   Das   Kurmi; Prashant      Kesharwani
Abstract

Morbidity, disability, and healthcare expenses associated with rheumatoid arthritis (RA) impose a considerable health and economical burden on both patients and healthcare systems. This review aimed to examine the pathophysiological aspects of RA that may help design different types of drugs and drug delivery systems. These include monoclonal antibodies, immunoglobulins, tiny chemicals, and transgenes for gene therapy. These novel nanocarrier-based therapies target the underlying biological processes involved in RA while minimizing the systemic adverse effects of drugs.
Keywords: Rheumatoid arthritis, nanocarriers, drug delivery, combination drug therapy, nanotherapeutics, nanomedicine.
[1]
Guo, Q.; Wang, Y.; Xu, D.; Nossent, J.; Pavlos, N.J.; Xu, J. Rheumatoid arthritis: Pathological mechanisms and modern pharmacologic therapies. Bone Res.,  2018, 6(1), 15.
 [http://dx.doi.org/10.1038/s41413-018-0016-9] [PMID: 29736302]

[2]
Ben Mrid, R.; Bouchmaa, N.; Ainani, H.; El Fatimy, R.; Malka, G.; Mazini, L. Anti-rheumatoid drugs advancements: New insights into the molecular treatment of rheumatoid arthritis. Biomed. Pharmacother.,  2022, 151, 113126.
 [http://dx.doi.org/10.1016/j.biopha.2022.113126] [PMID: 35643074]

[3]
Batko, B.; Korkosz, M.; Juś, A.; Wiland, P. Management of rheumatoid arthritis in Poland   where daily practice might not always meet evidence-based guidelines. Arch. Med. Sci.,  2021, 17(5), 1286-1293.
 [http://dx.doi.org/10.5114/aoms.2019.84092] [PMID: 34522257]

[4]
Mu oz-Mart nez, C.; Segura-Puertas, M.; G mez-Moreno, G. Disease-modifying Antirheumatic Drugs (DMARDs) and drug interactions in dentistry. Eur. Rev. Med. Pharmacol. Sci.,  2021, 25(7), 2834-2842.
 [PMID: 33877648]

[5]
Tanaka, Y. Recent progress in treatments of rheumatoid arthritis: An overview of developments in biologics and small molecules, and remaining unmet needs. Rheumatology (Oxford),  2021, 60(Suppl. 6), vi12-vi20.
 [http://dx.doi.org/10.1093/rheumatology/keab609] [PMID: 34951925]

[6]
Shukla, A.; Maiti, P. Nanomedicine and versatile therapies for cancer treatment. Med. Comm.,  2022, 3(3), e163.
 [http://dx.doi.org/10.1002/mco2.163]

[7]
Sargent, J. New nanomedicines for treating atherosclerotic plaques. Nat. Rev. Endocrinol.,  2015, 11(5), 256.
 [http://dx.doi.org/10.1038/nrendo.2015.35] [PMID: 25752278]

[8]
Moosavian, S.A.; Sathyapalan, T.; Jamialahmadi, T.; Sahebkar, A. The emerging role of nanomedicine in the management of nonalcoholic fatty liver disease: A state-of-the-art review. Bioinorg. Chem. Appl.,  2021, 10, 1-13.
 [http://dx.doi.org/10.1155/2021/4041415]

[9]
Oroojalian, F.; Karimzadeh, S.; Javanbakht, S.; Hejazi, M.; Baradaran, B.; Webster, T.J.; Mokhtarzadeh, A.; Varma, R.S.; Kesharwani, P.; Sahebkar, A. Current trends in stimuli-responsive nanotheranostics based on metal organic frameworks for cancer therapy. Mater. Today,  2022, 57, 192-224.
 [http://dx.doi.org/10.1016/j.mattod.2022.05.024]

[10]
Sanati, M.; Afshari, A.R.; Kesharwani, P.; Sukhorukov, V.N.; Sahebkar, A. Recent trends in the application of nanoparticles in cancer therapy: The involvement of oxidative stress. J. Control. Release,  2022, 348, 287-304.
 [http://dx.doi.org/10.1016/j.jconrel.2022.05.035] [PMID: 35644289]

[11]
Barendregt, A. Markers of inflammation: Measuring disease activity in juvenile idiopathic arthritis using imaging and immunological biomarkers; Graduate School Amsterdam Gastroenterology Endocrinology Metabolism (AMC), 2019. 

[12]
Elshal, M.; Abu-Elsaad, N.; El-Karef, A. Retinoic acid modulates IL-4, IL-10 and MCP-1 pathways in immune mediated hepatitis and interrupts CD4+ T cells infiltration. Int. Immunopharmacol.,  2019, 75, 105808.

[13]
Burmester, G.R.; Pope, J.E. Novel treatment strategies in rheumatoid arthritis. Lancet,  2017, 389(10086), 2338-2348.
 [http://dx.doi.org/10.1016/S0140-6736(17)31491-5]

[14]
Yap, H.Y.; Tee, S.; Wong, M.; Chow, S.K.; Peh, S.C.; Teow, S.Y. Pathogenic role of immune cells in rheumatoid arthritis: implications in clinical treatment and biomarker development. Cells,  2018, 7(10), 161.
 [http://dx.doi.org/10.3390/cells7100161] [PMID: 30304822]

[15]
Radu, A.F.; Bungau, S.G. Management of rheumatoid arthritis: An overview. Cells,  2021, 10(11), 2857.
 [http://dx.doi.org/10.3390/cells10112857] [PMID: 34831081]

[16]
McInnes, I.B.; Schett, G. The pathogenesis of rheumatoid arthritis. N. Engl. J. Med.,  2011, 365(23), 2205-2219.
 [http://dx.doi.org/10.1056/NEJMra1004965] [PMID: 22150039]

[17]
Aletaha, D.; Smolen, J.S. Diagnosis and management of rheumatoid arthritis. JAMA,  2018, 320(13), 1360-1372.
 [http://dx.doi.org/10.1001/jama.2018.13103] [PMID: 30285183]

[18]
Huang, J.; Fu, X.; Chen, X.; Li, Z.; Huang, Y.; Liang, C. Promising therapeutic targets for treatment of rheumatoid arthritis. Front. Immunol.,  2021, 12, 686155.
 [http://dx.doi.org/10.3389/fimmu.2021.686155] [PMID: 34305919]

[19]
Giacomelli, R.; Afeltra, A.; Alunno, A.; Baldini, C.; Bartoloni-Bocci, E.; Berardicurti, O. International consensus: What else can we do to improve diagnosis and therapeutic strategies in patients affected by autoimmune rheumatic diseases (rheumatoid arthritis, spondyloarthritides, systemic sclerosis, systemic lupus erythematosus, antiphospholipid syndrome and Sjogren's syndrome)?: The unmet needs and the clinical grey zone in autoimmune disease management. Autoimmun Rev.,  2017, 16(9), 911-924.

[20]
Mohammed, R.H.A. Introductory chapter: Rheumatoid arthritis - overview of current facts and strategies. In: Rheumatoid Arthritis; Intechopen Limited: London, 2020. 

[21]
Nagy, G.; Roodenrijs, N.M.; Welsing, P.M.; Kedves, M.; Hamar, A.; Van Der Goes, M.C. EULAR definition of difficult-to-treat rheumatoid arthritis. Ann. Rheum. Dis.,  2021, 80(9), 31-35.
 [http://dx.doi.org/10.1136/annrheumdis-2020-217344]

[22]
Wasson, J.H.; Sox, H.C.; Neff, R.K.; Goldman, L. Clinical prediction rules. Applications and methodological standards. N. Engl. J. Med.,  1985, 313(13), 793-799.
 [http://dx.doi.org/10.1056/NEJM198509263131306] [PMID: 3897864]

[23]
Wakefield, R.J.; Green, M.J.; Marzo-Ortega, H.; Conaghan, P.G.; Gibbon, W.W.; McGonagle, D.; Proudman, S.; Emery, P. Should oligoarthritis be reclassified? Ultrasound reveals a high prevalence of subclinical disease. Ann. Rheum. Dis.,  2004, 63(4), 382-385.
 [http://dx.doi.org/10.1136/ard.2003.007062] [PMID: 15020331]

[24]
Pilania, R.K.; Singh, S. Rheumatology panel in pediatric practice. Indian Pediatr.,  2019, 56(5), 407-414.
 [http://dx.doi.org/10.1007/s13312-019-1538-y] [PMID: 31102381]

[25]
Ingegnoli, F.; Castelli, R.; Gualtierotti, R. Rheumatoid factors: Clinical applications. Dis. Markers,  2013, 35(6), 727-734.
 [http://dx.doi.org/10.1155/2013/726598] [PMID: 24324289]

[26]
Girelli, F.; Foschi, F.G.; Bedeschi, E.; Calderoni, V.; Stefanini, G.F.; Martinelli, M.G. Is anti cyclic citrullinated peptide a useful laboratory test for the diagnosis of rheumatoid arthritis? Eur. Ann. Allergy Clin. Immunol.,  2004, 36(4), 127-130.
 [PMID: 15180353]

[27]
Alende-Castro, V.; Alonso-Sampedro, M.; Vazquez-Temprano, N.; Tu ez, C.; Rey, D.; Garc a-Iglesias, C.; Sope a, B.; Gude, F.; Gonzalez-Quintela, A. Factors influencing erythrocyte sedimentation rate in adults. Medicine (Baltimore),  2019, 98(34), e16816.
 [http://dx.doi.org/10.1097/MD.0000000000016816] [PMID: 31441853]

[28]
Crowson, C.S.; Rahman, M.U.; Matteson, E.L. Which measure of inflammation to use? A comparison of erythrocyte sedimentation rate and C-reactive protein measurements from randomized clinical trials of golimumab in rheumatoid arthritis. J. Rheumatol.,  2009, 36(8), 1606-1610.
 [http://dx.doi.org/10.3899/jrheum.081188] [PMID: 19531760]

[29]
Arnett, F.C.; Edworthy, S.M.; Bloch, D.A.; Mcshane, D.J.; Fries, J.F.; Cooper, N.S.; Healey, L.A.; Kaplan, S.R.; Liang, M.H.; Luthra, H.S.; Medsger, T.A.; Mitchell, D.M.; Neustadt, D.H.; Pinals, R.S.; Schaller, J.G.; Sharp, J.T.; Wilder, R.L.; Hunder, G.G. The American rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum.,  1988, 31(3), 315-324.
 [http://dx.doi.org/10.1002/art.1780310302] [PMID: 3358796]

[30]
Zaman, R.; Xiang, Y.; Cruz, J. Frequency and anatomic distribution of magnetic resonance imaging features in the sacroiliac joints of young athletes: Exploring  background noise  toward a data-driven definition of sacroiliitis in early spondyloarthritis. Arthritis Rheumatol.,  2018, 70(5), 736-745.

[31]
Hung, I.F.-N.; Lung, K.C.; Tso, E.Y.K.; Liu, R.; Chung, T.W.H.; Chu, M.Y. Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: An open-label, randomised, phase 2 trial. Lancet,  2020, 395(10238), 1695-1704.
 [http://dx.doi.org/10.1016/S0140-6736(20)31042-4]

[32]
Weber, U.; Jurik, A.G.; Zejden, A.; Larsen, E.; Rgensen, S.H.; Rufibach, K. Frequency and anatomic distribution of magnetic resonance imaging lesions in the sacroiliac joints of spondyloarthritis and non-spondyloarthritis patients. Sage J.,  2018, 70(5), 736-45.

[33]
Pawlik-Sobecka, L.; G rka-Dynysiewicz, J.; Kuciel-Lewandowska, J.J.A.S. Balneotherapy with the use of radon sulphide water. Mech. Ther. Eff.,  2021, 11(6), 2849.

[34]
Regueiro, C.; Rodr guez-Mart nez, L.; Nu o, L.; Ortiz, A.M.; Villalba, A.; Pascual-Salcedo, D. Improved RA classification among early arthritis patients with the concordant presence of three RA autoantibodies: Analysis in two early arthritis clinics. Arthritis Res Ther.,  2019, 21, 280.
 [http://dx.doi.org/10.1186/s13075-019-2079-4]

[35]
England, B.R.; Tiong, B.K.; Bergman, M.J.; Curtis, J.R.; Kazi, S.; Mikuls, T.R. 2019 Update of the American College of Rheumatology recommended rheumatoid arthritis disease activity measures. Arthritis Care Res. (Hoboken),  2019, 71(12), 1540-55.

[36]
Lewis, M.J.; Barnes, M.R.; Blighe, K.; Goldmann, K.; Rana, S.; Hackney, J.A. Molecular portraits of early rheumatoid arthritis identify clinical and treatment response phenotypes. Cell Rep.,  2019, 28(9), 2455-2470.
 [http://dx.doi.org/10.1016/j.celrep.2019.07.091]

[37]
Behrens, F.; Burmester, G.R.; Feuchtenberger, M.; Kellner, H.; Kuehne, C.; Liebhaber, A. Characterisation of depressive symptoms in rheumatoid arthritis patients treated with tocilizumab during routine daily care. Clin. Exp. Rheumatol.,  2022, 40(3), 551-559.

[38]
Brown, J.R. Frontiers in rheumatoid arthritis: Introduction. Am. J. Health-Sys. Pharm.,  2006, 63(18), S2.

[39]
Kean, W.F.; Kean, I.R.L. Clinical pharmacology of gold. Inflammopharmacology,  2008, 16(3), 112-125.
 [http://dx.doi.org/10.1007/s10787-007-0021-x] [PMID: 18523733]

[40]
Kavinaya, A. An Open comparative clinical evaluation on Uthiravadha Suronitham (Rheumatoid Arthritis) with siddha herbal mineral formulation drug Samuthara Chooranam (Internal), Vadha Noiku Veliprayogha Thailam (External) & Ottradam; Government Siddha Medical College: Chennai, 2018. 

[41]
Chatman-Terry, V. Leptin level variance in adults with and without cancer. Doctoral Dissertation, Walden University. 2019.

[42]
Sternak, M.; Bar, A.; Adamski, M.G.; Mohaissen, T.; Marczyk, B.; Kieronska, A. The deletion of endothelial sodium channel α (αENaC) impairs endothelium-dependent vasodilation and endothelial barrier integrity in endotoxemia in vivo. Front Pharmacol.,  2018, 9, 178.

[43]
Sandhu, R.S.; Treharne, G.J.; Douglas, K.M.J.; Cassim, K.; Saratzis, A.; Piper, H.; Erb, N.; Jenkins, D.; Tavakoli, M.; Deighton, C.; Kitas, G.D. The impact of anti-tumour necrosis factor therapy for rheumatoid arthritis on the use of other drugs and hospital resources in a pragmatic setting. Musculoskelet. Care,  2006, 4(4), 204-222.
 [http://dx.doi.org/10.1002/msc.92] [PMID: 17117445]

[44]
Singh, J.A.; Saag, K.G.; Bridges, S.L., Jr; Akl, E.A.; Bannuru, R.R.; Sullivan, M.C.; Vaysbrot, E.; McNaughton, C.; Osani, M.; Shmerling, R.H.; Curtis, J.R.; Furst, D.E.; Parks, D.; Kavanaugh, A.; O Dell, J.; King, C.; Leong, A.; Matteson, E.L.; Schousboe, J.T.; Drevlow, B.; Ginsberg, S.; Grober, J.; St Clair, E.W.; Tindall, E.; Miller, A.S.; McAlindon, T. 2015 American college of rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res. (Hoboken),  2016, 68(1), 1-25.
 [http://dx.doi.org/10.1002/acr.22783] [PMID: 26545825]

[45]
De Bandt, M. Anti-TNF-alpha-induced lupus. Arthritis Res. Ther.,  2019, 21(1), 235.
 [http://dx.doi.org/10.1186/s13075-019-2028-2] [PMID: 31718696]

[46]
Kim, K.U.; Kim, J.; Kim, W.H.; Min, H. Treatments of inflammatory bowel disease toward personalized medicine. Arch. Pharm. Res.,  2021, 44(3), 293-309.

[47]
Hamann, P.; Holland, R.; Hyrich, K.; Pauling, J.D.; Shaddick, G.; Nightingale, A.; McHugh, N. Factors associated with sustained remission in rheumatoid arthritis in patients treated with anti-tumor necrosis factor. Arthritis Care Res. (Hoboken),  2017, 69(6), 783-793.
 [http://dx.doi.org/10.1002/acr.23016] [PMID: 27564526]

[48]
Buch, M.H.; Eyre, S.; McGonagle, D.J.N.R.R. Persistent inflammatory and non-inflammatory mechanisms in refractory rheumatoid arthritis. Nat Rev Rheumatol.,  2021, 17(1), 17-33.

[49]
Gaeddert, A. Healing digestive disorders: Natural treatments for gastrointestinal conditions; PMPH USA, Ltd.: United States, 2018. 

[50]
Rubbert-Roth, A.; Szab , M.Z.; Kedves, M.; Nagy, G.; Atzeni, F. Failure of anti-TNF treatment in patients with rheumatoid arthritis: The pros and cons of the early use of alternative biological agents. Autoimmun. Rev.,  2019, 18(12), 102398.

[51]
Capell, H.A.; Madhok, R.; Porter, D.R.; Munro, R.A.L.; McInnes, I.B.; Hunter, J.A.; Steven, M.; Zoma, A.; Morrison, E.; Sambrook, M.; Wui Poon, F.; Hampson, R.; McDonald, F.; Tierney, A.; Henderson, N.; Ford, I. Combination therapy with sulfasalazine and methotrexate is more effective than either drug alone in patients with rheumatoid arthritis with a suboptimal response to sulfasalazine: Results from the double-blind placebo-controlled MASCOT study. Ann. Rheum. Dis.,  2006, 66(2), 235-241.
 [http://dx.doi.org/10.1136/ard.2006.057133] [PMID: 16926184]

[52]
Smolen, J.S.; Pangan, A.L.; Emery, P.; Rigby, W.; Tanaka, Y.; Vargas, J.I. Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (select-monotherapy): A randomised, placebo-controlled, double-blind phase 3 study. Lancet.,  2019, 393(10188), 2303-2311.

[53]
Kragsnaes, M.S.; Sødergren, S.T.; Kjeldsen, J.; Horn, H.C.; Munk, H.L.; Pedersen, J.K. Experiences and perceptions of patients with psoriatic arthritis participating in a trial of faecal microbiota transplantation: A nested qualitative study. BMJ Open.,  2021, 11(3), e039471.
 [http://dx.doi.org/10.1136/bmjopen-2020-039471]

[54]
David, V.; Walsh, M.; Lockyer, J.; Mintz, M.; Oleynick, C.; Motazedian, P. The SARS-CoV-19 pandemic one year later. Gen. Int. Med.,  2021, 16(1), 61.

[55]
van Riel, P.L.C.M.; Taggart, A.J.; Sany, J.; Gaubitz, M.; Nab, H.W.; Pedersen, R.; Freundlich, B.; MacPeek, D. Efficacy and safety of combination etanercept and methotrexate versus etanercept alone in patients with rheumatoid arthritis with an inadequate response to methotrexate: The ADORE study. Ann. Rheum. Dis.,  2006, 65(11), 1478-1483.
 [http://dx.doi.org/10.1136/ard.2005.043299] [PMID: 16464988]

[56]
Orbell, S. Automatic processes and self-regulation of illness. Health. Psychol. Rev.,  2019, 13(4), 378-405.

[57]
Van Hecke, O.; Raymond, M.; Lee, J.J.; Turner, P.; Goyder, C.R.; Verbakel, J.Y. In-vitro diagnostic point-of-care tests in paediatric ambulatory care: A systematic review and meta-analysis. PlusOne,  2020, 15(7), e0235605.
 [http://dx.doi.org/10.1371/journal.pone.0235605]

[58]
 Oon, S.; Huq, M.; Godfrey, T.; Nikpour, M. Systematic review, and meta-analysis of steroid-sparing effect, of biologic agents in randomized, placebo-controlled phase 3 trials for systemic lupus erythematosus. Semin. Arthritis Rheumatism, 2018, 48(2), 221-239. WB Saunders.
 [http://dx.doi.org/10.1016/j.semarthrit.2018.01.001]

[59]
Leiguarda, C.; Potilinski, C.; Rubione, J.; Tate, P.; Villar, M.J.; Montaner, A. IMT504 provides analgesia by modulating cell infiltrate and inflammatory milieu in a chronic pain model. J. Neuroimmune. Pharmacol.,  2021, 16(3), 651-666.

[60]
Yu, Z.; Reynaud, F.; Lorscheider, M.; Tsapis, N.; Fattal, E.J.W.I.R.N. Nanomedicines for the delivery of glucocorticoids and nucleic acids as potential alternatives in the treatment of rheumatoid arthritis. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol.,  2020, 12(45), e1630.

[61]
Paragliola, R.M.; Papi, G.; Pontecorvi, A. Treatment with synthetic glucocorticoids and the hypothalamus-pituitary-adrenal axis. Int. J. Mol. Sci.,  2017, 18(10), 2201.

[62]
Vadell, A.K.; Bärebring, L.; Hulander, E.; Gjertsson, I.; Lindqvist, H.M. Anti-inflammatory diet in rheumatoid arthritis (ADIRA) a randomized, controlled crossover trial indicating effects on disease activity. Am. J. Clin. Nutr.,  2020, 111(6), 1203-1213.

[63]
Ferra, F.; Ceccato, F.; Cannav, S. What we have to know about corticosteroids use during SARS-CoV-2 infection. J. Endocrinol. Invest.,  2021, 44(4), 693-701.

[64]
Green, D.; Dalmay, T. The role of small RNAs in Paget's associated osteosarcoma. J. Bone Oncol.,  2018, 13, 54.

[65]
Simpson, E.; Hock, E.; Stevenson, M.; Wong, R.; Dracup, N.; Wailoo, A. What is the added value of ultrasound joint examination for monitoring synovitis in rheumatoid arthritis and can it be used to guide treatment decisions? A systematic review and cost-effectiveness analysis. Health. Technol. Assess.,  2018, 22(20), 1-258.

[66]
Rao, M.; Ippolito, G.; Mfinanga, S.; Ntoumi, F.; Yeboah- Manu, D.; Vilaplana, C. Improving treatment outcomes for MDR-TB novel host-directed therapies and personalised medicine of the future. Int. J. Infect. Dis.,  2019, 80S(20), S62-S67.

[67]
Riches, S.; Khan, F.; Kwieder, S. Impact of an auditory hallucinations simulation on trainee and newly qualified clinical psychologists: A mixed-methods cross-sectional study. Clin. Psychol. Psychother.,  2019, 26(3), 277-290.

[68]
Hochberg, M. COX-2 selective inhibitors in the treatment of arthritis: A rheumatologist perspective. Curr. Top. Med. Chem.,  2005, 5(5), 443-448.
 [http://dx.doi.org/10.2174/1568026054201695] [PMID: 15974939]

[69]
Yang, X.; Li, M.; Jiang, J.; Hu, X.; Qing, Y.; Sun, L. Dysregulation of phospholipase and cyclooxygenase expression is involved in Schizophrenia. EBioMedicine,  2021, 64, 103239.
 [http://dx.doi.org/10.1016/j.ebiom.2021.103239]

[70]
Halpern, G.M. Ulcer Free!: Nature s Safe  Effective Remedy for Ulcers; Square One Publishers, Inc.: New York, 2004. 

[71]
Bullock, J.; Rizvi, S.A.A.; Saleh, A.M.; Ahmed, S.S.; Do, D.P.; Ansari, R.A.; Ahmed, J. Rheumatoid arthritis: A brief overview of the treatment. Med. Princ. Pract.,  2018, 27(6), 501-507.
 [http://dx.doi.org/10.1159/000493390] [PMID: 30173215]

[72]
Pham, C.T.N. Nanotherapeutic approaches for the treatment of rheumatoid arthritis. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol.,  2011, 3(6), 607-619.
 [http://dx.doi.org/10.1002/wnan.157] [PMID: 21837725]

[73]
Hu, G.; Guo, M.; Xu, J.; Wu, F.; Fan, J.; Huang, Q.; Yang, G.; Lv, Z.; Wang, X.; Jin, Y. Nanoparticles targeting macrophages as potential clinical therapeutic agents against cancer and inflammation. Front. Immunol.,  2019, 10, 1998.
 [http://dx.doi.org/10.3389/fimmu.2019.01998] [PMID: 31497026]

[74]
Deighton, C.; Criswell, L.A. Recent advances in the genetics of rheumatoid arthritis. Curr. Rheumatol. Rep.,  2006, 8(5), 394-400.
 [http://dx.doi.org/10.1007/s11926-006-0071-x] [PMID: 16973114]

[75]
Ozbakir, B.; Crielaard, B.J.; Metselaar, J.M.; Storm, G.; Lammers, T. Liposomal corticosteroids for the treatment of inflammatory disorders and cancer. J. Control. Release,  2014, 190, 624-636.
 [http://dx.doi.org/10.1016/j.jconrel.2014.05.039] [PMID: 24878183]

[76]
Alten, R.; D ring, G.; Cutolo, M.; Gromnica-Ihle, E.; Witte, S.; Straub, R.; Buttgereit, F. Hypothalamus-pituitary-adrenal axis function in patients with rheumatoid arthritis treated with nighttime-release prednisone. J. Rheumatol.,  2010, 37(10), 2025-2031.
 [http://dx.doi.org/10.3899/jrheum.100051] [PMID: 20682671]

[77]
Bartneck, M.; Peters, F.M.; Warzecha, K.T.; Bienert, M.; van Bloois, L.; Trautwein, C.; Lammers, T.; Tacke, F. Liposomal encapsulation of dexamethasone modulates cytotoxicity, inflammatory cytokine response, and migratory properties of primary human macrophages. Nanomedicine,  2014, 10(6), 1209-1220.
 [http://dx.doi.org/10.1016/j.nano.2014.02.011] [PMID: 24607939]

[78]
Gomez-Barrena, E.; Lindroos, L.; Ceponis, A.; L pez-Franco, M.; Sanchez-Pernaute, O.; M nkk nen, J.; Salo, J.; Herrero-Beaumont, G.; Konttinen, Y. Cartilage oligomeric matrix protein (COMP) is modified by intra-articular liposomal clodronate in an experimental model of arthritis. Clin. Exp. Rheumatol.,  2006, 24(6), 622-628.
 [PMID: 17207376]

[79]
Ceponis, A.; Waris, E.; M nkk nen, J.; Laasonen, L.; Hyttinen, M.; Solovieva, S.A.; Hanemaaijer, R.; Bitsch, A.; Konttinen, Y.T. Effects of low-dose, noncytotoxic, intraarticular liposomal clodronate on development of erosions and proteoglycan loss in established antigen-induced arthritis in rabbits. Arthritis Rheum.,  2001, 44(8), 1908-1916.
 [http://dx.doi.org/10.1002/1529-0131(200108)44:8<1908::AID-ART329>3.0.CO;2-4] [PMID: 11508444]

[80]
Li, S.; Su, J.; Cai, W.; Liu, J. Nanomaterials manipulate macrophages for rheumatoid arthritis treatment. Front. Pharmacol.,  2021, 12, 699245.
 [http://dx.doi.org/10.3389/fphar.2021.699245] [PMID: 34335264]

[81]
Jorgensen, C.; Apparailly, F. Prospects for gene therapy in inflammatory arthritis. Best Pract. Res. Clin. Rheumatol.,  2010, 24(4), 541-552.
 [http://dx.doi.org/10.1016/j.berh.2010.02.001] [PMID: 20732651]

[82]
Ghosh, S.; Brown, A.M.; Jenkins, C.; Campbell, K. Viral vector systems for gene therapy: A comprehensive literature review of progress and biosafety challenges. Appl. Biosaf.,  2020, 25(1), 7-18.
 [http://dx.doi.org/10.1177/1535676019899502] [PMID: 36033383]

[83]
Duan, W.; Li, H. Combination of NF-kB targeted siRNA and methotrexate in a hybrid nanocarrier towards the effective treatment in rheumatoid arthritis. J. Nanobiotechnology,  2018, 16(1), 58.
 [http://dx.doi.org/10.1186/s12951-018-0382-x] [PMID: 30060740]

[84]
Khoury, M.; Louis-Plence, P.; Escriou, V.; Noel, D.; Largeau, C.; Cantos, C.; Scherman, D.; Jorgensen, C.; Apparailly, F. Efficient new cationic liposome formulation for systemic delivery of small interfering RNA silencing tumor necrosis factor α in experimental arthritis. Arthritis Rheum.,  2006, 54(6), 1867-1877.
 [http://dx.doi.org/10.1002/art.21876] [PMID: 16729293]

[85]
Khoury, M.; Escriou, V.; Courties, G.; Galy, A.; Yao, R.; Largeau, C.; Scherman, D.; Jorgensen, C.; Apparailly, F. Efficient suppression of murine arthritis by combined anticytokine small interfering RNA lipoplexes. Arthritis Rheum.,  2008, 58(8), 2356-2367.
 [http://dx.doi.org/10.1002/art.23660] [PMID: 18668557]

[86]
Nagata, Y.; Nakasa, T.; Mochizuki, Y.; Ishikawa, M.; Miyaki, S.; Shibuya, H.; Yamasaki, K.; Adachi, N.; Asahara, H.; Ochi, M. Induction of apoptosis in the synovium of mice with autoantibody-mediated arthritis by the intraarticular injection of double-stranded microRNA-15a. Arthritis Rheum.,  2009, 60(9), 2677-2683.
 [http://dx.doi.org/10.1002/art.24762] [PMID: 19714650]

[87]
Sobus, K.M. Rehabilitation care and management for the individual with cerebral palsy, ages 13 through early adulthood. Crit. Rev. Phys. Rehabil. Med.,  2009, 21(2), 117-165.

[88]
Chen, M.; Daddy, J.C.K.A.; Xiao, Y.; Ping, Q.; Zong, L. Advanced nanomedicine for rheumatoid arthritis treatment: Focus on active targeting. Expert Opin. Drug Deliv.,  2017, 14(10), 1141-1144.
 [http://dx.doi.org/10.1080/17425247.2017.1372746] [PMID: 28847165]

[89]
Xiao, S.; Tang, Y.; Lv, Z.; Lin, Y.; Chen, L. Nanomedicine   advantages for their use in rheumatoid arthritis theranostics. J. Control. Release,  2019, 316, 302-316.
 [http://dx.doi.org/10.1016/j.jconrel.2019.11.008] [PMID: 31715278]

[90]
Nakashima-Matsushita, N.; Homma, T.; Yu, S.; Matsuda, T.; Sunahara, N.; Nakamura, T.; Tsukano, M.; Ratnam, M.; Matsuyama, T. Selective expression of folate receptor? and its possible role in methotrexate transport in synovial macrophages from patients with rheumatoid arthritis. Arthritis Rheum.,  1999, 42(8), 1609-1616.
 [http://dx.doi.org/10.1002/1529-0131(199908)42:8<1609::AID-ANR7>3.0.CO;2-L] [PMID: 10446858]

[91]
Siouti, E.; Andreakos, E. The many facets of macrophages in rheumatoid arthritis. Biochem. Pharmacol.,  2019, 165, 152-169.
 [http://dx.doi.org/10.1016/j.bcp.2019.03.029] [PMID: 30910693]

[92]
Costa, C.; Incio, J.; Soares, R. Angiogenesis and chronic inflammation: Cause or consequence? Angiogenesis,  2007, 10(3), 149-166.
 [http://dx.doi.org/10.1007/s10456-007-9074-0] [PMID: 17457680]

[93]
Szekanecz, Z.; Besenyei, T.; Szentp tery; Koch, A.E. Angiogenesis and vasculogenesis in rheumatoid arthritis. Curr. Opin. Rheumatol.,  2010, 22(3), 299-306.
 [http://dx.doi.org/10.1097/BOR.0b013e328337c95a] [PMID: 20305562]

[94]
Merchant, B. Gold, the noble metal and the paradoxes of its toxicology. Biologicals,  1998, 26(1), 49-59.
 [http://dx.doi.org/10.1006/biol.1997.0123] [PMID: 9637749]

[95]
Tsai, C.Y.; Shiau, A.L.; Chen, S.Y.; Chen, Y.H.; Cheng, P.C.; Chang, M.Y.; Chen, D.H.; Chou, C.H.; Wang, C.R.; Wu, C.L. Amelioration of collagen-induced arthritis in rats by nanogold. Arthritis Rheum.,  2007, 56(2), 544-554.
 [http://dx.doi.org/10.1002/art.22401] [PMID: 17265489]

[96]
Kim, W.U.; Lee, W.K.; Ryoo, J.W.; Kim, S.H.; Kim, J.; Youn, J.; Min, S.Y.; Bae, E.Y.; Hwang, S.Y.; Park, S.H.; Cho, C.S.; Park, J.S.; Kim, H.Y. Suppression of collagen-induced arthritis by single administration of poly(lactic-co-glycolic acid) nanoparticles entrapping type II collagen: A novel treatment strategy for induction of oral tolerance. Arthritis Rheum.,  2002, 46(4), 1109-1120.
 [http://dx.doi.org/10.1002/art.10198] [PMID: 11953991]

[97]
Nagashima, M.; Wauke, K.; Hirano, D.; Ishigami, S.; Aono, H.; Takai, M.; Sasano, M.; Yoshino, S. Effects of combinations of anti-rheumatic drugs on the production of vascular endothelial growth factor and basic fibroblast growth factor in cultured synoviocytes and patients with rheumatoid arthritis. Rheumatology (Oxford),  2000, 39(11), 1255-1262.
 [http://dx.doi.org/10.1093/rheumatology/39.11.1255] [PMID: 11085806]

[98]
Fernandes, J.C.; Wang, H.; Jreyssaty, C.; Benderdour, M.; Lavigne, P.; Qiu, X.; Winnik, F.M.; Zhang, X.; Dai, K.; Shi, Q. Bone-protective effects of nonviral gene therapy with folate-chitosan DNA nanoparticle containing interleukin-1 receptor antagonist gene in rats with adjuvant-induced arthritis. Mol. Ther.,  2008, 16(7), 1243-1251.
 [http://dx.doi.org/10.1038/mt.2008.99] [PMID: 18500247]

[99]
Courties, G.; Baron, M.; Presumey, J.; Escriou, V.; van Lent, P.; Scherman, D.; Cantagrel, A.; van den Berg, W.B.; Jorgensen, C.; Apparailly, F.; Davignon, J.L. Cytosolic phospholipase A2α gene silencing in the myeloid lineage alters development of Th1 responses and reduces disease severity in collagen-induced arthritis. Arthritis Rheum.,  2011, 63(3), 681-690.
 [http://dx.doi.org/10.1002/art.30174] [PMID: 21360497]

[100]
Howard, K.A.; Paludan, S.R.; Behlke, M.A.; Besenbacher, F.; Deleuran, B.; Kjems, J. Chitosan/siRNA nanoparticle- mediated TNF-alpha knockdown in peritoneal macrophages for anti-inflammatory treatment in a murine arthritis model. Mol. Ther.,  2009, 17(1), 162-168.
 [http://dx.doi.org/10.1038/mt.2008.220] [PMID: 18827803]

[101]
Butoescu, N.; Seemayer, C.A.; Foti, M.; Jordan, O.; Doelker, E. Dexamethasone-containing PLGA superparamagnetic microparticles as carriers for the local treatment of arthritis. Biomaterials,  2009, 30(9), 1772-1780.
 [http://dx.doi.org/10.1016/j.biomaterials.2008.12.017] [PMID: 19135244]

[102]
Hwang, J.; Rodgers, K.; Oliver, J.C.; Schluep, T. Alpha-methylprednisolone conjugated cyclodextrin polymer-based nanoparticles for rheumatoid arthritis therapy. Int. J. Nanomedicine,  2008, 3(3), 359-371.
 [PMID: 18990945]

[103]
Metselaar, J.M.; Wauben, M.H.M.; Wagenaar-Hilbers, J.P.A.; Boerman, O.C.; Storm, G. Complete remission of experimental arthritis by joint targeting of glucocorticoids with long-circulating liposomes. Arthritis Rheum.,  2003, 48(7), 2059-2066.
 [http://dx.doi.org/10.1002/art.11140] [PMID: 12847701]

[104]
Arias, J.L.; L pez-Viota, M.; L pez-Viota, J.; Delgado, V. Development of iron/ethylcellulose (core/shell) nanoparticles loaded with diclofenac sodium for arthritis treatment. Int. J. Pharm.,  2009, 382(1-2), 270-276.
 [http://dx.doi.org/10.1016/j.ijpharm.2009.08.019] [PMID: 19712736]

[105]
Liu, M.; Huang, Y.; Hu, L.; Liu, G.; Hu, X.; Liu, D.; Yang, X. Selective delivery of interleukine-1 receptor antagonist to inflamed joint by albumin fusion. BMC Biotechnol.,  2012, 12(1), 68.
 [http://dx.doi.org/10.1186/1472-6750-12-68] [PMID: 23006786]

[106]
Coppieters, K.; Dreier, T.; Silence, K.; Haard, H.D.; Lauwereys, M.; Casteels, P.; Beirnaert, E.; Jonckheere, H.; Wiele, C.V.D.; Staelens, L.; Hostens, J.; Revets, H.; Remaut, E.; Elewaut, D.; Rottiers, P. Formatted anti tumor necrosis factor α VHH proteins derived from camelids show superior potency and targeting to inflamed joints in a murine model of collagen-induced arthritis. Arthritis Rheum.,  2006, 54(6), 1856-1866.
 [http://dx.doi.org/10.1002/art.21827] [PMID: 16736523]

[107]
Thao, L.Q.; Byeon, H.J.; Lee, C.; Lee, S.; Lee, E.S.; Choi, H.G.; Park, E.S.; Youn, Y.S. Pharmaceutical potential of tacrolimus-loaded albumin nanoparticles having targetability to rheumatoid arthritis tissues. Int. J. Pharm.,  2016, 497(1-2), 268-276.
 [http://dx.doi.org/10.1016/j.ijpharm.2015.12.004] [PMID: 26657273]

[108]
Fiehn, C.; Neumann, E.; Wunder, A.; Krienke, S.; Gay, S.; M ller-Ladner, U. Methotrexate (MTX) and albumin coupled with MTX (MTX-HSA) suppress synovial fibroblast invasion and cartilage degradation in vivo. Ann. Rheum. Dis.,  2004, 63(7), 884-886.
 [http://dx.doi.org/10.1136/ard.2003.013748] [PMID: 15194591]

[109]
Lee, H.; Lee, M.Y.; Bhang, S.H.; Kim, B.S.; Kim, Y.S.; Ju, J.H.; Kim, K.S.; Hahn, S.K. Hyaluronate-gold nanoparticle/tocilizumab complex for the treatment of rheumatoid arthritis. ACS Nano,  2014, 8(5), 4790-4798.
 [http://dx.doi.org/10.1021/nn500685h] [PMID: 24730974]

[110]
Duan, J.; Dong, J.; Zhang, T.; Su, Z.; Ding, J.; Zhang, Y.; Mao, X. Polyethyleneimine-functionalized iron oxide nanoparticles for systemic siRNA delivery in experimental arthritis. Nanomedicine (Lond.),  2014, 9(6), 789-801.
 [http://dx.doi.org/10.2217/nnm.13.217] [PMID: 24392891]

[111]
Samarasinghe, R.M.; Kanwar, R.K.; Kanwar, J.R. The effect of oral administration of iron saturated-bovine lactoferrin encapsulated chitosan-nanocarriers on osteoarthritis. Biomaterials,  2014, 35(26), 7522-7534.
 [http://dx.doi.org/10.1016/j.biomaterials.2014.04.109] [PMID: 24933511]

[112]
Lee, S.J.; Lee, A.; Hwang, S.R.; Park, J.S.; Jang, J.; Huh, M.S.; Jo, D.G.; Yoon, S.Y.; Byun, Y.; Kim, S.H.; Kwon, I.C.; Youn, I.; Kim, K. TNF-α gene silencing using polymerized siRNA/thiolated glycol chitosan nanoparticles for rheumatoid arthritis. Mol. Ther.,  2014, 22(2), 397-408.
 [http://dx.doi.org/10.1038/mt.2013.245] [PMID: 24145554]

[113]
Kim, M.J.; Park, J.S.; Lee, S.J.; Jang, J.; Park, J.S.; Back, S.H.; Bahn, G.; Park, J.H.; Kang, Y.M.; Kim, S.H.; Kwon, I.C.; Jo, D.G.; Kim, K. Notch1 targeting siRNA delivery nanoparticles for rheumatoid arthritis therapy. J. Control. Release,  2015, 216, 140-148.
 [http://dx.doi.org/10.1016/j.jconrel.2015.08.025] [PMID: 26282098]

[114]
Zhou, H.; Hu, G.; Wickline, S.A.; Lanza, G.M.; Pham, C.T.N. Synergistic effect of antiangiogenic nanotherapy combined with methotrexate in the treatment of experimental inflammatory arthritis. Nanomedicine (Lond.),  2010, 5(7), 1065-1074.
 [http://dx.doi.org/10.2217/nnm.10.78] [PMID: 20874021]

[115]
Heo, R.; Park, J.S.; Jang, H.J.; Kim, S.H.; Shin, J.M.; Suh, Y.D.; Jeong, J.H.; Jo, D.G.; Park, J.H. Hyaluronan nanoparticles bearing γ-secretase inhibitor: In vivo therapeutic effects on rheumatoid arthritis. J. Control. Release,  2014, 192, 295-300.
 [http://dx.doi.org/10.1016/j.jconrel.2014.07.057] [PMID: 25109660]

[116]
Scheinman, R.I.; Trivedi, R.; Vermillion, S.; Kompella, U.B. Functionalized STAT1 siRNA nanoparticles regress rheumatoid arthritis in a mouse model. Nanomedicine (Lond.),  2011, 6(10), 1669-1682.
 [http://dx.doi.org/10.2217/nnm.11.90] [PMID: 22087799]

[117]
Ye, J.; Wang, Q.; Zhou, X.; Zhang, N. Injectable actarit-loaded solid lipid nanoparticles as passive targeting therapeutic agents for rheumatoid arthritis. Int. J. Pharm.,  2008, 352(1-2), 273-279.
 [http://dx.doi.org/10.1016/j.ijpharm.2007.10.014] [PMID: 18054182]

[118]
Arora, R.; Kuhad, A.; Kaur, I.P.; Chopra, K. Curcumin loaded solid lipid nanoparticles ameliorate adjuvant-induced arthritis in rats. Eur. J. Pain,  2015, 19(7), 940-952.
 [http://dx.doi.org/10.1002/ejp.620] [PMID: 25400173]

[119]
Aggarwal, B.B.; Harikumar, K.B. Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases. Int. J. Biochem. Cell Biol.,  2009, 41(1), 40-59.
 [http://dx.doi.org/10.1016/j.biocel.2008.06.010] [PMID: 18662800]

[120]
Srinath, P.; Chary, M.G.; Vyas, S.P.; Diwan, P.V. Long-circulating liposomes of indomethacin in arthritic rats - a biodisposition study. Pharm. Acta Helv.,  2000, 74(4), 399-404.
 [http://dx.doi.org/10.1016/S0031-6865(00)00023-6] [PMID: 10812940]
Cite As
Current Medicinal Chemistry

Recent Advances in Drug Delivery Approaches for Rheumatoid Arthritis

Abstract
